Stock Code: 300363 stock abbreviation: Porton Pharma Solutions Ltd(300363) Announcement No.: 2022-003 Porton Pharma Solutions Ltd(300363)
Performance forecast for 2021
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Expected performance of the current period
1. Performance forecast period: January 1, 2021 – December 31, 2021
2. Expected performance: turning loss into profit √ rising and falling in the same direction
3. Performance forecast
The current reporting period of the project is the same period of last year
Year on year growth: 54% – 64%
Net profit attributable to shareholders of listed companies: 324.42 million yuan; Profit: 500 million yuan – 532 million yuan
Deduction attributable to shareholders of listed companies increased by 80% – 90% over the same period of last year
Profit: 288.23 million yuan net profit from recurring profit and loss: 518.8 million yuan – 547.65 million yuan
Year on year growth: 45% – 50%
Operating income: 2071.88 million yuan; income: 3004.22 million yuan – 3107.81 million yuan
4. Impact of non recurring profit and loss on the company’s net profit
In 2021, the impact of the company’s non recurring profits and losses on the net profit was about – 7 million yuan, and 36.19 million yuan in 2020.
2、 Performance forecast and pre audit
The financial data related to this performance forecast has not been audited by certified public accountants.
3、 Explanation of performance change reasons
In 2021, under the background of the steady growth of global pharmaceutical R & D pipeline and the increasing trend of pharmaceutical R & D and production outsourcing, the company continues to expand and enrich product pipeline, continuously improve technical capacity, product delivery capacity and order acquisition capacity, and is expected to achieve an increase of 45% – 50% in operating revenue compared with the same period of last year. Meanwhile, with the further improvement of the company’s capacity utilization and operation efficiency, as well as the further optimization of product structure, the company’s profitability continues to improve. The company expects to achieve a year-on-year increase of 54% – 64% in net profit attributable to shareholders of Listed Companies in 2021, and a year-on-year increase of 80% – 90% in net profit attributable to shareholders of listed companies after deducting non recurring profits and losses in 2021. In 2021, the two new business segments of the company’s preparation cdmo and gene cell therapy cdmo continued to “build capacity, build reputation and expand the market”, which was still in the stage of loss as a whole, reducing the net profit attributable to the shareholders of the listed company in the consolidated statements by about 100 million yuan.
4、 Other relevant instructions
The performance forecast is preliminarily calculated by the company’s finance department, and the specific financial data will be disclosed in detail in the company’s 2021 annual report. Please make prudent decisions and pay attention to investment risks.
It is hereby announced.
Porton Pharma Solutions Ltd(300363) board of directors January 16, 2022
